Aims To assess the efficacy of buprenorphine compared with methadone maintenance therapy for opioid dependence in a large sample using a flexible dosing regime and the marketed buprenorphine tablet. Design Patients were randomized to receive buprenorphine or methadone over a 13-week treatment period in a double-blind, double-dummy trial. Setting Three methadone clinics in Australia. Participants Four hundred and five opioid-dependent patients seeking treatment. Intervention Patients received buprenorphine or methadone as indicated clinically using a flexible dosage regime. During weeks 1-6, patients were dosed daily. From weeks 7-13, buprenorphine patients received double their week 6 dose on alternate days. Measurements Retention in treatment, and illicit opioid use as determined by urinalysis. Self-reported drug use, psychological functioning, HIV-risk behaviour, general health and subjective ratings were secondary outcomes. Findings Intention-to-treat analyses revealed no significant difference in completion rates at 13 weeks. Methadone was superior to buprenorphine in time to termination over the 13-week period (Wald c 2 = 4.371, df = 1, P = 0.037), but not separately for the single-day or alternate-day dosing phases. There were no significant between-group differences in morphine-positive urines, or in selfreported heroin or other illicit drug use. The majority (85%) of the buprenorphine patients transferred to alternate-day dosing were maintained in alternate-day dosing. Conclusions Buprenorphine did not differ from methadone in its ability to suppress heroin use, but retained approximately 10% fewer patients. This poorer retention was due possibly to too-slow induction onto buprenorphine. For the majority of patients, buprenorphine can be administered on alternate days.
INTRODUCTION
As reviewed elsewhere (Ward, Hall & Mattick 1999) , buprenorphine (a partial mu-opioid agonist) has been researched as an alternative to methadone (a full opioid agonist) for the treatment of opioid dependence, both as a maintenance agent and as an effective medication for reducing withdrawal severity during opioid withdrawal (Mattick & Hall 1996) . A number of randomized clinical trials have reported that buprenorphine and methadone are equally effective in maintenance therapy of opioiddependent patients (Johnson, Jaffe & Fudala 1992 ; Strain Richard P. Mattick et al. et al . 1994a; Strain et al . 1994b; Johnson et al . 2000; Pani et al . 2000) . However, an equivalent number of studies have reported inferior results for buprenorphine (Kosten et al . 1993; Ling et al . 1996; Schottenfeld et al . 1997; Fischer et al . 1999; Petitjean et al . 2001) . Usually, these latter authors attribute the inferiority of buprenorphine to doses of buprenorphine that are too low (Kosten et al . 1993; Ling et al . 1996; Schottenfeld et al . 1997; Fischer et al . 1999; Petitjean et al . 2001 ), or to slow induction onto low doses of buprenorphine (Uehlinger et al . 1998; Fischer et al . 1999) . Also, two recent metaanalytical reviews suggested a small advantage of methadone over buprenorphine (West, O'Neal & Graham 2000; Barnett, Rodgers & Bloch 2001) .
Notably, the studies reporting poor results for buprenorphine have all used either fixed doses of both buprenorphine and methadone, or had maximum doses of methadone below the recognized therapeutic range of 50-100 mg per day (Ward, Mattick & Hall 1998) , or buprenorphine below a maximum daily dose of 32 mg. The lack of flexible dosing and the failure to use full dose ranges makes it difficult to draw confident conclusions about the relative efficacy of these two medications in day-to-day practice.
These problems of interpretation are further compounded by the use of an ethanol-based aqueous formulation of buprenorphine in most of the double-blind trials, excluding two studies from Europe (Pani et al . 2000; Petitjean et al . 2001 ). This aqueous preparation has been reported to have greater bioavailability than the marketed buprenorphine tablet (Mendelson et al . 1995 ). The few flexible dose studies which have been reported relied on the ethanol-based aqueous formulation of buprenorphine (Strain et al . 1994a; Strain et al . 1994b; Johnson et al . 2000) . Finally, many of the studies reported to date have used small sample sizes, with individual group sizes usually in the range of 24-38 patients in six studies (Kosten et al . 1993; Strain et al . 1994a; Schottenfeld et al . 1997; Fischer et al . 1999; Pani et al . 2000; Petitjean et al . 2001) , and 84 patients being the largest individual group size reported to date (Strain et al . 1994b) .
It seemed possible that the dose range restrictions and low maximum dose in many studies, plus the lower bioavailability of the marketed tablet, and the small sample size in many of the studies, all compromised confident interpretation of the results of the trials to clinical practice, and these factors could explain the conflicting findings reported in those trials. The present trial was designed to assess the efficacy of buprenorphine in a large sample of opioid-dependent patients, with a flexible dosing regime tailored to the clinical need of the patients, with high maximum doses, using the marketed tablet formulation, under double-blind conditions. Additionally, we chose to offer alternate-day dosing for buprenorphine after stabilisation, as this is likely to be a frequent method of buprenorphine prescribing in actual practice.
METHODS

Inclusion/exclusion criteria
Patients were eligible for the study if they: had a current diagnosis of opioid dependence using the criteria in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association 1994); were aged 18 years or older; lived within commuting distance of the clinic; appeared mentally competent to give informed consent; and signed informed consent.
Patients were excluded from the study if they were: pregnant or nursing, or were deemed likely to become pregnant in the study period; suffering an acute medical condition that could make participation in the study medically hazardous (e.g. active tuberculosis, unstable cardiovascular or serious acute liver disease); currently using anticonvulsant medication, disulfiram, or antipsychotic medication; in opioid replacement treatment (methadone was the only available medication at the time of the study) in the preceding 30 days (and this status was verified from state department of health records); unable to attend the clinic daily for the study period; in a study of buprenorphine previously, or were currently in another clinical trial.
Enrolment and randomization
After research staff assessed the patients' drug use and completed the research interview, a medical practitioner trained and accredited in methadone prescribing independently verified eligibility and enrolled the patients in the trial. A central pharmacist, responsible for the preparation of the active and placebo doses, then assigned the patient a study number from a computer-generated allocation sequence (provided by the Sponsor directly to the dispensing pharmacy). This randomization process relied on sealed envelopes not seen or accessible by the research or clinical staff, kept locked in a secure area of the pharmacy separate from the clinical dosing area and available to the dispensing pharmacist only. The dispensing pharmacist who conducted the randomization was not involved in assessing the eligibility of patients for the trial or on any efficacy variable. Patients were randomized to buprenorphine or methadone in consecutive numerical order. A separate randomization schedule was used for each site, with randomization stratified according to gender, in fixed block sizes of 10 patients (five patients each to methadone or buprenorphine). Prescribing doctors, staff conducting the dosing, research and counselling staff and patients were unaware of treatment assignment.
Recruitment occurred from July 1996 until August 1998, with follow-up of 13 weeks.
Study design
This study was conducted at three public clinics, two located in the city of Sydney and one in Adelaide, specializing in the treatment of opioid dependence. The study assessed the comparative efficacy, safety and acceptability of sublingual buprenorphine tablets with oral methadone syrup, which was the only available opioid replacement therapy in Australia at the time. A randomized, controlled, parallel group design was utilized under double-blind, double-placebo conditions. Patients were randomized to receive one active medication (either methadone or buprenorphine) and one placebo medication (either placebo syrup or placebo tablets), so that all patients received both tablets and syrup at each dosing occasion.
During weeks 1-6, all patients received their active medication daily. For weeks 7-13, patients randomized to active buprenorphine received double their week 6 dose every second day, and the corresponding number of placebo tablets on the alternate days. To maintain the blind, patients randomized to methadone also received double their week 6 'dose' of placebo buprenorphine tablets every day. There were no planned changes to the methadone syrup doses, active or placebo, during this time. If a patient randomized to active buprenorphine did not attend daily for dosing, the 'timing' of the active tablets was not altered. Patients were not terminated from the study unless a number of consecutive days of dosing were missed (5 or 7 days, according to usual practice at the clinic). A flexible dosage regime was employed with doses prescribed by experienced medical officers as clinically indicated. Four ethics committees, including one medical research ethics committee for each of the three sites, and one university research ethics committee approved the clinical protocols and the consent procedures.
Dosing protocol
Sublingual buprenorphine tablets containing either 2 mg or 8 mg of buprenorphine and matching sublingual placebo tablets were used (supplied by the Sponsor). Oral methadone (obtained from Glaxo Smith Kline, Boronia, Australia) was in the form of a solution/syrup. The same source prepared the placebo methadone, which was identical in volume and general appearance to active methadone, and contained the solution/syrup vehicle plus an appropriate amount of a bittering agent (denatonium benzoate) for taste matching. Both the active and placebo methadone syrup were mixed with cordial of various flavours at the time of dispensing. Subjects received study medications in the following order: (1) sublingual tablets were administered first; followed by (2) syrup topped-up with cordial; and then (3) an optional other liquid (cordial or water) if requested. The sublingual tablet(s) were placed under the tongue and allowed to dissolve. The tablets were taken all at once, and patients were instructed they were not to be chewed or swallowed. Dissolution normally occurred within 5 minutes (with a minimum of 2 minutes). Clinic staff checked under patients' tongues for dissolution of the tablets. The order of administration was designed to minimize the potential for subjects to divert medications, or leave the clinic before the sublingual medication had fully dissolved. No take-away doses of medications were allowed.
In order to maintain the blind, medical officers prescribed doses of methadone for all patients, with buprenorphine doses 'yoked' to methadone doses. For those who were maintained on buprenorphine, the phar- macist used the buprenorphine doses shown in Table 1 . Dose changes of methadone were allowed only in units of 10 mg. Maximum doses were 150 mg for methadone and 32 mg for buprenorphine.
Induction
As this was a flexible dose study, the individual daily doses that were used varied from patient to patient based on their individual needs within Australian guidelines. Induction doses across all sites were set at 20-40 mg oral methadone (and 2-6 mg buprenorphine), in line with Australian policy. During this period patients could request dose changes which were implemented in accordance with standardized policy across the sites, based on withdrawal signs or toxicity/sedation being present.
Alternate-day buprenorphine dosing
On day 1 of week 7, patients on buprenorphine were transferred to alternate-day dosing. As the nurses, prescribers and patients were unaware of the medication patients were receiving, any patient complaining that they were not sufficiently 'held' during this alternate-day dosing period could receive a dose adjustment. If the patient was on an alternate-day dose of 32 mg and was assessed by the clinic methadone prescriber as showing objective signs of withdrawal and/or complaints of symptoms, they were returned to single-day dosing regime. Before returning patients to a daily dosing regime, and in order to ascertain that these patients' concerns/complaints were genuine the Short Opiate Withdrawal Scale (SOWS) (Gossop 1990 ) was completed by the patient and used in conjunction with a checklist of objective withdrawal signs and symptoms completed by a prescriber.
Evaluation procedures
A variety of assessments were undertaken as detailed below. The main efficacy criteria were days of retention in treatment and the results of urine analysis for opioids. If a patient was terminated from the study for any reason, the date of the last study dose was considered the termination date. Urine samples were analysed for the presence of morphine, benzodiazepines, amphetamine and cocaine. The samples were collected on a random basis from each patient fortnightly and patients were advised that the results were not reported to clinic staff and would not affect their treatment. If a patient failed to give a sample on the day it was due, it was recorded as missing and a 'replacement' sample requested within 24 hours. The urine containers included temperature strips, which were monitored by clinic staff to ensure that there was no tampering with samples.
Self-report questionnaires administered on a specific day throughout each week were used to assess drug use, alcohol consumption, adverse and serious adverse events in the previous 7 days, and withdrawal symptoms for the past 24 hours. Using the SOWS (Gossop 1990) , patients were required to rate their experience of 10 symptoms of withdrawal on a scale ranging from 0 to 3 (0 denoting 'none' and 3 'severe'). The maximum score that could be achieved on this scale was 30, which would represent severe withdrawal, the minimum 0.
Weekly ratings were also made of feelings of comfort/ discomfort ('holding'), intoxication ('buzz'), dependence ('hooked'), liking of the medication ('like'), whether the medication made the patient feel 'normal' and the perceived severity of 'drug problem'. The research staff also rated the perceived severity of 'drug problem'. All these ratings used a scale of 0-100, with 0 representing an absence of the effect or problem. Weekly ratings of peak heroin and alcohol cravings were also measured with a visual analogue scale. At baseline and at the end of the 13-week trial, the Opiate Treatment Index (Darke et al . 1992 ) was administered and provided data on drug use, crime, physical health, psychological functioning and HIV risk behaviour.
Data monitoring and data entry
The study data collection was monitored by the Sponsor and by an independent contract research organization. The study was conducted according to the Australian national guidelines for good clinical research practice (Therapeutic Goods Administration 1991). All data queries raised by the trial monitors were resolved. All data were entered twice, on the second occasion using blinded data entry and any discrepancies resolved.
Statistical analysis plan
A statistical analysis plan (SAP) was formulated prior to data analysis. The main aim of the double-blind comparison was to compare the efficacy of buprenorphine and methadone in decreasing illicit opioid use and associated problems in opioid-dependent patients. An 'intention-totreat' (ITT) population was defined as those patients who entered the study and received at least one dose of study medication. All summaries and analyses were based on this 'intention-to-treat' population (cf. Johnson et al . 2000) . In each of the analyses, terms for site, gender, age and age ¥ gender interaction were included. Efficacy analyses were carried out by the Sponsor in the United Kingdom using SAS, and the analyses were run independently by an analyst in Australia using SAS. The latter analyses were conducted with the analyst blind to the treatment types being compared. The results from the two analyses were identical.
Analysis of primary efficacy assessments
The primary efficacy parameters were retention in treatment and the absence of morphine in urine samples. Retention in treatment was analysed using two variables: numbers completing the study and time to termination. A binary variable indicated if the patient completed the study or terminated early. This was compared between treatment groups using binomial logistic regression. The time to termination was defined as the number of days from the first dose of study medication to completion (91 days) or, for those who terminated early, to the last dose of study medication. The time to termination was compared between treatment groups using log-rank analysis (i.e. the Cox proportional hazards model).
Two analyses were undertaken on the urine data. For the first analysis (planned), failure to provide a sample on the assigned day was treated as 'missing' and, hence, could not count as 'clean urines'. The second analysis (actual) included all urine samples obtained (i.e. 'planned' and 'replacement' samples). For both sets of urine analyses, two variables were derived as follows. The percentage of clean urines (PCU) was the number of clean urine samples recorded for each patient expressed as a percentage of the total number of samples which could have been provided during the time that the patient remained in the study. The treatment effectiveness percentage (TEP) was the number of clean urine samples recorded for each patient expressed as a percentage of the total number of samples which should have been provided during the full 13-week study (i.e. seven samples). The PCU and TEP variables, were transformed using the empirical logistic transformation to normalize the distribution, and were compared between treatment groups using analysis of covariance.
Secondary efficacy assessments
An Opiate Treatment Index (OTI) (Darke et al . 1991 ) and the Symptom Checklist-90-R (SCL-90-R ® ) (Derogatis 1994) were completed at baseline and at the end of the study (13 weeks). The OTI assessed the major domains of heroin and other drug use, HIV-risk taking behaviour, social functioning, criminality, physical health and psychological status. Only patients who completed the study had the opportunity to complete the follow-up assessment and, hence, the analysis was limited to these patients. These parameters were compared between treatment groups using analysis of covariance of the ranked values (Nonpar-ANCOVA ). The series of subjective assessments made at weekly intervals throughout the study were summarised using a modified area under the curve (AUCM) approach. These were compared between treatment groups using Nonpar-ANCOVA .
Safety assessments
The number of patients experiencing adverse events was recorded and the most common were compared between treatment groups.
RESULTS
Patients
Four hundred and five patients were enrolled in the trial across three sites (199, 105 and 101 at three public methadone clinics). Eleven of the 405 patients who were randomized following assessment failed to return to the clinic for a dose and were not included in the efficacy analyses (Fig. 1) . 
Demographic characteristics
There were no statistically significant differences between the two groups in terms of the patient demographic characteristics or drug dependence and history variables. Among the whole sample, 31% were female and the average age was 30 years. There were no between-group differences in, severity of dependence, age of first use, duration of use, craving, or the global severity of 'drug problem' as rated by research staff and patient. Demographic and drug use variables are presented in Table 2 .
Study retention
Patients in the buprenorphine group were retained in treatment for a mean of 59.2 days (SD = 35.9), while patients in the methadone group were in treatment for a mean of 66.8 days (SD = 33.1). Overall, 54.8% of the 394 patients who received at least one dose of medication completed the 13-week trial. The percentage of patients in each group at the end of each treatment week is shown in Fig. 2 . A greater percentage of methadone patients (59%) completed the trial than buprenorphine patients (50%) (Fig. 2 ), but this difference was not statistically significant (c 2 = 3.516, df = 1, P = 0.061). There was a significant difference in retention between the groups across the 13-week period applying a survival analysis (i.e. a Cox proportional hazards model) (Wald c 2 = 4.371, df = 1, P = 0.037). There was no difference between the groups in the first 6 weeks (Wald c 2 = 3.751, df = 1, P = 0.053), or in the buprenorphine alternate-day dosing period (Wald c 2 = 0.417, df = 1, P = 0.519).
Urinalyses
The relative percentages of morphine-free urine samples for each group are displayed in Fig. 3 . Inspection of the data does not show any clear pattern of superiority for either medication. Two methods of analysing the data were undertaken. The PCU gives a more favourable score to those patients who remain 'drug-free' but terminate the study early. The TEP takes into account how long patients should remain in the study and, hence, is less favourable to patients who terminate early for reasons The results of the analysis using 'planned' samples obtained, showed that for the PCU variable there was no between-group difference (F = 1.26, df = 6, 354, P = 0.262). Similarly, for the TEP variable there was no between-group difference (F = 0.10, df = 6, 387, P = 0.757). There were also no between-group differences when data from weeks 1-6 and weeks 7-13 were analysed separately.
The evaluation of the urine results in an alternative way, using all samples obtained including replacement samples (i.e. actual), showed a similar lack of significant difference between the groups. For the PCU variable there was no between-group difference (F = 0.19, df = 6, 344, P = 0.666). The TEP variable also showed no betweengroup difference (F = 1.09, df = 6, 383, P = 0.296). A similar lack of significant difference between groups was observed when data from weeks 1-6 and weeks 7-13 were analysed separately.
Based on 'planned' samples (excluding the baseline sample), the mean number of morphine positive urine samples was 3.14 (SD = 2.49) for the buprenorphine group and 3.62 (SD = 2.38) for the methadone group. Based on the 'actual' samples, the mean number of morphine-positive urine samples was 2.47 (SD = 2.24) for the buprenorpine group and 2.86 (SD = 2.28) for the methadone group.
Self-reported drug use
There was a reduction from baseline to 13 weeks in the self-reported daily heroin use and on the other opiate use variables on the Opiate Treatment Index, but no significant between-group differences were observed at 13 weeks (P > 0.05). Similarly, there were no significant differences between the groups at 13 weeks in selfreported use of alcohol, cannabis, amphetamines, cocaine, tranquillizers or polydrug use based on selfreport using the Opiate Treatment Index (Darke et al. 1992) . These data are presented in Table 3 .
There was no between-group difference across the 13 weeks of the trial in self-reported weekly heroin use (see Fig. 4 ). The data on alcohol use collected in the weekly forms showed that the proportion of patients using alcohol in the buprenorphine group did not change, whereas this reduced in the methadone group across the 13 weeks of the trial (F = 5.89, df = 6, 356, P = 0.016). However, the average level of alcohol consumption reported by both groups was low, ranging from a minimum mean of 0.5 standard drinks per week to a maximum of 1.2 standard drinks per week for the buprenorphine group and 0.2-0.6 per week for the methadone group. MMT = methadone maintenance treatment; BMT = buprenorphine maintenance treatment. a There were no between-group differences at the 0.05 significance level.
Other measures
There were significant overall improvements, but no difference between groups, in self-reported HIV-risk behaviour, social functioning, physical health or psychological morbidity (GHQ and SCL90R), and there were significant reductions in criminal activity in both groups. There was no difference between the groups in the weekly ratings of the feelings described 'holding', 'hooked', 'like', whether the medication made the patient feel 'normal', and the perceived severity of 'drug problem' as rated by the patient and by the research staff analysed across the 13 weeks of the trial. However, methadone was rated as better 'liked' by the methadone group in weeks 1-6 of the trial compared to the rating given to buprenorphine by the buprenorphine patients (F = 7.24, df = 6, 351, P = 0.0075). Methadone was also rated as giving more of a 'buzz' in comparison to buprenorphine across the duration of the trial (F = 10.60, df = 6, 352, P = 0.0012). The Short Opiate Withdrawal Scale was completed by patients as part of their 'patient daily forms' requirements on a weekly basis. Overall, both groups rated their experience of withdrawal for the past 24 hours as relatively mild and abating over time in the study (week 1 to week 13 mean SOWS scores for the methadone group, and buprenorphine group were: 6, 8; 6, 7; 5, 6; 5, 6; 5, 6; 5, 5; 4, 5; 4, 6; 4, 5; 4, 5; 4, 5; 4, 4; 4, 3) . The buprenorphine group generally rated their experience of withdrawal as greater than the methadone group from weeks 1-13, a difference which was significant across the study (F = 6.81, df = 6, 346, P = 0.0094).
Adverse and serious adverse events
There was no attempt to compare statistically the rate of adverse events recorded between the sites or between the medications. The serious adverse events recorded were (with frequencies for the methadone and buprenorphine group, respectively): acute attack of hepatitis C: 1, 0; allergic reaction: 0, 1; assault on patient: 2, 1; motor vehicle accident: 0, 1; overdose on heroin or heroin plus benzodiazepines: 0, 4; pneumonia: 0, 1: suicide attempt: 0, 1. Treatment emergent adverse events are presented in Table 4 .
Daily and alternate-day dosing
Alternate-day dosing commenced at the start of week 7. At that time, 96% of the buprenorphine patients in treatment were transferred to receive active buprenorphine every second day, and placebo buprenorphine on the other days. Four per cent of patients were not transferred to alternate-day dosing, as they were deemed too erratic in their attendance to be transferred safely. Of the patients in the buprenorphine treatment group who transferred to alternate-day dosing, the vast majority stayed in alternate-day dosing. Only 11% of all buprenorphine patients in treatment at week 7 returned to daily dosing, and in total 85% of all buprenorphine patients in treatment at week 7 stayed in alternate-day dosing. As shown Symptoms shown have an incidence of 5% in either randomized group.
in Table 5 , the average doses of both medications increased over the first few weeks, as patients achieved a stable dose. At week 6 the average buprenorphine dose was 10.9 mg/day, and 11.2 mg/day during weeks 12 and 13. The average dose of methadone in week 6 was 52.6 mg/day, increasing slowly to 57.3 mg/day in week 13.
DISCUSSION
The results of the trial indicate that methadone and buprenorphine were both effective in treating opioid dependence, both producing clinically and statistically significant reductions in illicit opioid use, improvements in self-reported physical health and psychological wellbeing, improvements in social functioning, as well as reductions in HIV risk-behaviour and criminal activity. The changes in wellbeing are consistent with the benefits reported in the early studies of methadone maintenance treatment (Dole et al. 1969; Newman & Whitehill 1979; Gunne & Grönbladh 1981) , and support the view that opioid replacement therapy is an important intervention for these patients. In this double-blind randomized trial, retention in treatment was assessed in two ways: by the numbers completing the study and time to termination. A greater proportion of methadone patients (59.4%) completed the 13-week trial than buprenorphine patients (50.0%), but this difference was not significant. With respect to time to termination, there was a statistically significant difference between buprenorphine and methadone over the 13-week period, but not when analysed separately for the single-day or alternate-day dosing phases. Therefore, of four tests of retention, only one indicated a significant difference between buprenorphine and methadone maintenance treatment, rasing the possibility of a type one error. Indeed, if the type one error rate of the four tests of retention were adjusted for multiple testing, the single significant difference (P = 0.037) would become nonsignificant (adjusted a= 0.05/4 = 0.0125). Some studies comparing methadone and buprenorphine have not observed methadone to have superior retention compared to buprenorphine (Johnson, Jaffe & Fudala 1992; Strain et al. 1994a; Strain et al. 1994b; Johnson et al. 2000; Pani et al. 2000) , whereas others have found methadone to retain patients better. Where differences in retention have favoured methadone, it is usually the case that the authors have attributed the poorer retention of buprenorphine maintained patients to one of two factors: slow induction onto buprenorphine (Fischer et al. 1999; Petitjean et al. 2001) or low maximum doses of that medication (Kosten et al. 1993; Oliveto et al. 1994; Ling et al. 1996; Schottenfeld et al. 1997; Fischer et al. 1999; Petitjean et al. 2001) . The second problem has been addressed in this study by use of flexible dosing that was largely driven by patient needs. However, slow induction may still have been a factor in the retention rate differential as the small difference in retention in the current study developed in the first two weeks of treatment, with the retention curves essentially parallel thereafter. Four explanations may account for this steeper early drop-out rate in our buprenorphine group. First, as mentioned above, the doses of buprenorphine used in the present study may have been too low during the induction phase and not increased quickly enough to retain a proportion of the patients, compared with methadone. Mean withdrawal scores were significantly higher for the buprenorphine group than the methadone group, although clinically the difference was minimal, and withdrawal scores were quite low overall. The majority of buprenorphine patients received between 2 mg and 6 mg of buprenorphine daily in the first week of dosing, and it may be that very rapid induction to doses of up to 12-16 mg is required to maximize retention when using a partial agonist, a question that deserves further research. Given the safety profile of buprenorphine, such rapid dose escalation may not create any clinical management problems or serious adverse events, except possibly in combination with benzodiazepines (Reynaud et al. 1998) . A second possibility is that a subset of patients absorbs buprenorphine poorly and achieves suboptimal blood levels (either because of a physiological rate-limiting step or due to poor patient 'management' of the tablets sublingually), an effect reported by others who showed marked variability in bioavailability from the buprenorphine tablet compared with the aqueous solution (Mendelson et al. 1995). A third possibility is that buprenorphine's partial agonist properties are simply unattractive to some patients who prefer to have a full-agonist effect, and consistent with this hypothesis the buprenorphine patients reported lower 'liked' and 'buzz' ratings. Finally, it may be that buprenorphine is easier to withdraw from for some patients (Cheskin, Fudala & Johnson 1994) , allowing them greater ability to leave treatment without marked withdrawal discomfort. Obviously, these mechanisms may all operate together to produce a slightly greater drop-out early in buprenorphine treatment than in methadone treatment. A study of very rapid versus slower induction onto high-dose buprenorphine, assessing buprenorphine blood levels during induction, and determining patient satisfaction with buprenorphine's opioid effect and reasons for leaving treatment in the induction phase, may help to tease apart the relative importance of these potential factors.
With regard to illicit drug use, there was no difference in the two medications in their ability to suppress heroin use, as shown by random urine analyses. There was also no difference in self-reported injecting of heroin, and urine test results for morphine showed equal rates of morphine-free samples. There was no difference between the two treatments in other illicit drug use. A significant difference was noted between the number of patients reporting weekly alcohol use in each group which appeared driven largely by a reduction among the methadone group rather than changes among the buprenorphine group. Although not significant, there was also a trend of greater levels of weekly alcohol consumption among the buprenorphine group, an observation that others have noted (Strain et al. 1994a) . Any interpretation of these results should take into consideration the low levels of alcohol use reported by both groups. Further, most studies of buprenorphine do not report on levels of alcohol use, so it is difficult to comment whether this is a reliable finding or a chance result.
There was some ongoing heroin use in the sample, albeit greatly attenuated. It is possible that methadone could have had a greater impact than buprenorphine on heroin use had the doses of methadone been above the levels prescribed. However, three points need to be borne in mind when considering this issue. The doses used were the typical doses employed in the three clinics involved, each of which had a maintenance (rather than an abstinence) orientation. The study protocol used a policy of allowing experienced clinicians in these large clinics to set doses as they normally would, rather than constrain their practices artificially. Our doses were similar to those in the only other double-blind, flexible-dose studies reported (Strain et al. 1994a; Strain et al. 1994b) . While others have shown that fixed high doses of methadone (e.g. 80 mg or 65 mg) can produce better outcomes than fixed low doses of buprenorphine (e.g. 8 mg or 4 mg) (Ling et al. 1996; Schottenfeld et al. 1997) , when fixed higher doses of methadone (65 mg) and higher doses of buprenorphine (12 mg) are compared there is no significant difference in suppression of opioid use, and no difference in retention (Schottenfeld et al. 1997) . Reports from the United Kingdom (Gossop et al. 1999) , United States (Strain et al. 1994a; Strain et al. 1994b) and Australia (Bell et al. 1997) all indicate that the methadone doses used in this study were in the typically prescribed range. Finally, even if it were accepted that higher doses of methadone could produce different outcomes than reported herein, one has to consider whether patients will accept high doses.
Importantly, the results show that alternate-day dosing of buprenorphine is feasible and does not cause problems for the vast majority of patients. There was no increased attrition with buprenorphine, relative to methadone, during the double-blinded alternate-day dosing phase in this study. Others have recently reported that thrice-weekly dosing is feasible (Johnson et al. 2000) , although more opioid-positive urines are found in patients in thrice-weekly dosing than daily buprenorphine dosing (Perez de los Cobos et al. 2000) . None the less, less than daily dosing of buprenorphine would seem to combine effectiveness with patient convenience, and may carry some cost-savings for the patient and the health system by reducing the frequency of attending for dosing, and increase the capacity of the treatment system. It may also provide a benefit to communities by reducing attendance and congregation around busy clinics.
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